key: cord-0896040-1l10diya authors: Apicella, Matteo; Campopiano, Maria Cristina; Mantuano, Michele; Mazoni, Laura; Coppelli, Alberto; Del Prato, Stefano title: COVID-19 in people with diabetes: understanding the reasons for worse outcomes date: 2020-07-17 journal: Lancet Diabetes Endocrinol DOI: 10.1016/s2213-8587(20)30238-2 sha: 679fc0eaf9277f0fccae493c85af63843eb86708 doc_id: 896040 cord_uid: 1l10diya Since the initial COVID-19 outbreak in China, much attention has focused on people with diabetes because of poor prognosis in those with the infection. Initial reports were mainly on people with type 2 diabetes, although recent surveys have shown that individuals with type 1 diabetes are also at risk of severe COVID-19. The reason for worse prognosis in people with diabetes is likely to be multifactorial, thus reflecting the syndromic nature of diabetes. Age, sex, ethnicity, comorbidities such as hypertension and cardiovascular disease, obesity, and a pro-inflammatory and pro-coagulative state all probably contribute to the risk of worse outcomes. Glucose-lowering agents and anti-viral treatments can modulate the risk, but limitations to their use and potential interactions with COVID-19 treatments should be carefully assessed. Finally, severe acute respiratory syndrome coronavirus 2 infection itself might represent a worsening factor for people with diabetes, as it can precipitate acute metabolic complications through direct negative effects on β-cell function. These effects on β-cell function might also cause diabetic ketoacidosis in individuals with diabetes, hyperglycaemia at hospital admission in individuals with unknown history of diabetes, and potentially new-onset diabetes. In December, 2019, a cluster of cases of atypical interstitial pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China. Following the rapid spread of COVID-19, WHO on March 11, 2020, declared COVID-19 a global pandemic. As a result, social contain ment measures have been adopted worldwide and health-care systems reorganised to cope with a growing number of acutely ill patients. At the time this Review was written, more than 12 million cases and more than 550 000 deaths have been reported worldwide. 1 Among those with severe COVID-19 and those who died, there is a high prevalence of concomitant conditions including diabetes, cardiovascular disease, hyper tension, obesity, and chronic obstruc tive pulmonary disease. 2 The fatality rate is particularly high in older patients, in whom comorbidities are common. 2 Most of the available information refers to patients with type 2 diabetes, 3,4 and in this Review we mainly refer to patients with type 2 diabetes, unless otherwise stated. In previous disease epidemics, a greater risk of viral infection was observed in people with diabetes. 5 This does not seem to be the case for COVID-19, 1 though diabetes is more common among those with severe COVID-19. Data from two hospitals in Wuhan including 1561 patients with COVID-19 showed that those with diabetes (9·8%) were more likely to require admission to an intensive care unit (ICU) or to die. 6 Similarly, in a British cohort of 5693 patients with COVID-19 in hospital, the risk of death was more common in those with uncontrolled diabetes (hazard ratio [HR] 2·36, 95% CI 2·18-2·56). 7 Whether such worse prognosis is due to diabetes per se or to concomitant morbidities and risk factors remains to be fully elucidated. This Review is, therefore, intended to provide a systematic assessment of potential prognostic factors in patients with diabetes with COVID-19. Diabetes is known to confer increased risk for infections. Previous studies have shown a J-curve relationship between HbA 1c and risk of being admitted to hospital for infections in general, and infections of the respiratory tract in particular. An increased risk of infection was reported during previous outbreaks of severe acute respiratory syndrome, 5 Middle East respiratory syndrome, 8 and H1N1 influenza virus; 9 however, this doesn't seem to be the case for COVID- 19 . In an analysis, the prevalence of diabetes in 1590 Chinese patients with COVID-19 was 8·2%, similar to the prevalence of diabetes in China. However, the prevalence of diabetes rose to 34·6% in patients with severe COVID-19. 10 In a meta-analysis of six Chinese studies, the prevalence of diabetes was 9·7% in the whole COVID-19 cohort (n=1527), similar to the estimated diabetes prevalence in China (10·9%). 11 In 146 patients with a mean age of 65·3 years admitted to hospital for COVID-19 in northern Italy, a prevalence of diabetes of 8·9% was reported, slightly lower than the diabetes prevalence in the same region for the same age stratum (11%). 12 Diabetes does not seem to increase the risk of COVID-19 occurring, although diabetes is more frequent in patients with severe COVID-19 (table 1) . In a Chinese retrospective study, patients with diabetes had more severe pneumonia, higher concentrations of lactate dehy dro genase, α-hydroxybutyrate dehydrogenase, alanine aminotransferase, and γ-glutamyl transferase, and fewer lymphocytes with a higher neutrophil count. In the same study, a subgroup of 24 patients with diabetes had greater mortality compared to 26 patients without diabetes (16·5% vs 0%). 21 In a prospective cohort study of patients with COVID-19 from New York City (NY, USA), the prevalence of diabetes and obesity was higher in individuals admitted to hospital than those not admitted to hospital (34·7% vs 9·7% for diabetes and 39·5% vs 30·8% for obesity, respectively). 13 In a meta-analysis of Review eight studies, 14 patients with COVID-19 with diabetes had an increased risk of ICU admission. In a retrospective study 13 of 191 patients with COVID-19 admitted to hospital, compared with survivors (n=137) those who died (n=54) had a higher prevalence of hypertension (23% vs 48%), diabetes (14% vs 31%), and coronary heart disease (1% vs 24%). In Italy, an analysis 22 of 27 955 patients who died from COVID-19 showed a prevalence of diabetes of 31·1%. A survey done in England (UK) 20 showed that of 23 804 patients with COVID-19 dying in hospital, 32% had type 2 diabetes and 1·5% had type 1 diabetes, with 2·03 and 3·5 times the odds of dying compared with patients without diabetes, respectively. In the French population of the CORONADO study, 23 3% had type 1 diabetes, 88·5% had type 2 diabetes, 5·4% had other type diabetes, and 3·1% were diagnosed at admission. A further study 24 showed adjusted HRs with HbA 1c greater than 86 mmol/mol (10%) compared with HbA 1c 48-53 mmol/mol (6·5%-7·0%) of 2·19 (95% CI 1·46-3·29) for type 1 diabetes and 1·62 (95% CI 1·48-1·79) for type 2 diabetes. In summary, patients with COVID-19 with diabetes have a worse prognosis, most probably because of the concurring effect of multiple factors. In an American survey, 25 33 individuals with type 1 diabetes with COVID-19 were identified; they were young (mean age 24·8 years [SD 17·49]), with high glucose concentrations at presentation and diabetic ketoacidosis reported in 45·5% of the cases. Similar to those with type 2 diabetes, obesity, hypertension, and cardiovascular disease were the most common comorbidities. Age, sex, and ethnicity Older age and male sex are epidemiological features related to a higher prevalence of COVID-19 and a more severe clinical course. In the early phase of the outbreak, the highest prevalence of COVID-19 occurred in older people in most of the regions of the world, with the exception of South Korea 26 where the highest rate of confirmed SARS-CoV-2 infection occurred in those aged 20-29 years. However, an increased prevalence in those below the age of 30 years has been recently observed in Florida (USA), most probably due to social reasons. In all other countries the highest prevalence of COVID-19 has been in older people. In a large case series of the Chinese pandemic (72 314 cases, updated to Feb 11, 2020), 27 the peak of morbidity was in people aged 50-59 years. The overall case-fatality rate was 2·3% but this increased up to 14·8% in individuals aged 80 years and older. The prevalence of diabetes increases with age in both the general population and in patients with COVID-19. Accordingly, the average age of patients with COVID-19 with diabetes is older than those without diabetes. In one survey, 28 patients with diabetes were at least 10 years older than patients without diabetes. Moreover, age was associated with a greater odds ratio (OR) of in-hospital death that was similar in individuals without diabetes (multivariate OR 1·09, 95% CI 1·07-1·12) and those with diabetes (1·09, 1·04-1·15). A separate study 6 of a matched population of patients with COVID-19 with and without diabetes reported that survivors were younger than nonsurvivors, with age 70 years and older being an independent predictor of in-hospital death (no diabetes HR 5·87, 95% CI 1·88-18·33; diabetes HR 2·39, 1·03-5·56). Despite overall similar sex distribution of people infected with SARS-CoV-2, (male 51%, female 49%), the case-fatality rate has been higher in males (2·8%) than in females (1·7%). 19 A study 7 confirmed age and male sex as risk factors for worse outcomes in COVID-19, with those aged 80 years and older having a 12-times higher risk compared with those aged 50-59 years and males having twice the risk as females (HR 1·99, 95% CI 1·88-2·10). Non-white ethnic groups seem to be at greater risk as indicated by HRs adjusted for age and sex ranging between 1·83 and 2·17 for black, Asian or Asian British, and mixed ethnicities compared with white people. 7 This finding confirms a US report on a link between racial minorities and worse outcomes from COVID-19. An analysis 29 reported that in 131 predominantly black counties in the USA, infection and death rates were more than three times and six times higher, respectively, than in predominantly white counties. In New York City, Hispanic or Latin people account for 28% of the population, but 34% of COVID-19 deaths. 29 In New Mexico, Native Americans represent 11% of the population, but 37% of COVID-19 cases. 29 The higher incidence and worse outcomes of COVID-19 reported in ethnic minority groups are unlikely to reflect biological factors, and are predominantly due to lifestyle and socioeconomic factors. Although data fully adjusted for comorbidities are not yet available, a higher prevalence of cardiovascular risk factors such as hypertension, diabetes, and obesity in ethnic minorities compared with the white population might partly account for the increased risk of poor outcome in these minority populations. These populations are also more likely to be socioeconomically disadvantaged as they more often live in poor and overcrowded houses and are employed in jobs requiring human interaction with resulting increased exposure to the risk of virus transmission. However, in India, Pakistan, and Bangladesh, despite a high prevalence of diabetes and deprivation, a relatively low COVID-19 mortality has been reported so far. 31 This finding has suggested a potential geographical or climatic effect on the spreading of the infection. However, a careful geopolitical analysis 32 considering latitude, temperature, and humidity could only find a weak negative association with relative humidity. In summary, available data suggest that age is associated with worse outcomes in COVID-19, and it can be hypothesised that this relationship is stronger in people with diabetes for at least three reasons. First, the prevalence of diabetes increases with age to reach a peak in people older than 65 years. Second, people older than 65 years are more likely to have a longer duration of diabetes and a greater prevalence of diabetic complications. Third, diabetes and older age often correlate with comorbidities such as cardiovascular disease, hypertension, and obesity. In a retrospective analysis of patients with COVID-19, 6 those with diabetes had a greater prevalence of hypertension (56·9%), cardiovascular disease (20·9%), and cerebro vascular disease (7·8%) than those without diabetes (28·8%, 11·1%, and 1·3%, respectively). Moreover, in the patients with diabetes, non-survivors had a greater prevalence of comorbidities than survivors (hypertension 83·9% vs 50·0%; cardiovascular disease 45·2% vs 14·8%; cerebrovascular disease 126·1% vs 5·7%; chronic pulmonary disease 12·9% vs 3·3%; and chronic kidney disease 6·5% vs 3·3%). In a Cox multiregression analysis, 6 in patients with diabetes but not in those without diabetes, hypertension (HR 3·10, 95% CI 1·14-8·44), cardiovascular disease (1·87, 0·88-4·00), and chronic pulmonary disease (2·77, 0·90-8·54) were independent risk factors for in-hospital death. These findings were also noted in 136 patients with diabetes of 904 patients with COVID-19. 28 In the patients with COVID-19, those with diabetes more commonly had hyper tension, cardiovascular disease, nervous system disease, and chronic kidney disease; cardio vascular disease, nervous system disease, and chronic kidney disease were all associated with risk for in-hospital death and poor prognosis. In the CORONADO study, 23 an estimated glomerular filtration rate on admission to hospital of 60 mL/min per 1·73 m² or less was an independent predictor of early death in patients with diabetes. SARS-CoV-2 might directly target the kidney through an angiotensin-converting enzyme (ACE) 2-dependent pathway, causing acute renal impairment and increased lethality. 33 Arterial hypertension is by far the most frequent comorbidity seen in patients with COVID-19. 34 It has been speculated that the high prevalence of the infection could be due to use of ACE inhibitors since SARS-CoV-2 binds to ACE2 to enter target cells. 35 ACE2 is expressed in the lung, heart, liver, kidney, ileum, and brain and is physiologically involved in anti-inflammatory responses. 36 Experimental evidence 37, 38 suggests that ACE inhibitors and angiotensin receptor blockers increase the expression of ACE2, and it was proposed that these drugs could facilitate target organ infection and promote progression of the disease. However, this evidence was obtained in in vitro and animal studies. Given its structural differences with ACE, ACE2 does not represent a target of these drugs. 37 Moreover, the interaction between ACE inhibitors and the renin-angiotensin system is complex and not completely understood in humans. 39 SARS-CoV-2 has been claimed to increase the expression of angiotensin II with subsequent downregulation of ACE2 and loss of anti-inflammatory effect in the respiratory tract, resulting in alveolar wall thickening, oedema, inflammatory infiltration, and bleeding. Moreover, a favourable effect of ACE inhibitors and angiotensin receptor blockers on the risk of community acquired pneumonia, especially in Asian populations, has been suggested. 40 Initial reports 14 on 8910 patients with COVID-19 from 11 countries could not detect an association between ACE inhibitors or angiotensin receptor blockers and the risk of in-hospital death. A population-based case-control study 41 from Lombardy, an Italian region particularly affected by the pandemic, led to similar conclusions. A Chinese study has even shown a lower rate of severe diseases and a trend toward a lower inflammatory response in 17 patients with COVID-19 treated with ACE inhibitors or angiotensin receptor blockers versus 25 patients given other anti-hypertensive drugs. 42 In summary, ACE inhibitors are unlikely to account for the association between COVID-19 and hypertension. 43 Patients with COVID-19 have a high prevalence of cardiovascular disease. 11 Cases of acute myocarditis associated with COVID-19 have been reported 44 and a direct myocardial injury has been postulated. The evidence for myocardial injury is largely indirect, with no evidence of viral genomes from myocardial biopsy samples. 45 In an autopsy report 46 for 23 patients with COVID-19, 13 showed cardiac manifestations, along with pulmonary involvement. Three patients had obesity and had multifocal acute cardiomyocyte injury without inflammatory cellular infiltrates, lymphocytic myocarditis, or lymphocytic pericarditis associated with signs of chronic cardiac disease. In a metaanalysis 47 of 4189 patients from 28 observational studies, patients with more severe COVID-19 had higher troponin concentrations, which was associated with an increased risk of death. A manifestation of secondary cardiac involvement in COVID-19 is stress-induced (Takotsubo) cardio myo pathy. 45 Cardiovascular complications might also develop because of reduced systemic oxygenation due to pneumonia and concomitant increased cardiac demand, by immune dysregulation, electrolyte imbalance, or because of adverse effects of drugs such as hydroxy chloroquine and azithromycin. 48 Many reports have linked obesity to more severe COVID-19 illness and death. 6,23,49 Several mechanisms can account for this association. The first concerns the detrimental restrictive ventilatory effect of abdominal fat. 50 In a French study, 51 the risk for invasive mechanical ventilation in patients with COVID-19 admitted to an ICU was more than seven times higher in those with a BMI of more than 35 kg/m² than those with a BMI of less than 25 kg/m². Second, in addition to the ventilatory defect, the respiratory dysfunction in patients with severe COVID-19 might depend on impaired lung perfusion due to intravascular disseminated coagu lation. 52 In line with this hypothesis, low-molecular-weight heparin was found to reduce mortality. 53 Obesity and diabetes are prothrombotic conditions that might contribute to worse prognosis in patients with COVID-19. In an autopsy study from Germany, 54 deep venous thrombosis was found in seven of 12 patients (58%) and pulmonary embolism was the direct cause of death in four. Of these patients, the BMI of those who died from pulmonary embolism was 36·8 kg/m². Finally, obesity is associated with immune dysregulation and chronic inflammation that could mediate progression toward organ failure in severe COVID-19 patients. Myocarditis and cardiomyocyte dysfunction could be worsened by local biological effects of epicardial adipose tissue, 55 a source of adipokines and pro-inflammatory mediators, and the volume of epicardial adipose tissue is directly associated with BMI. 56 Moreover, ACE2 is highly expressed in the epicardial adipose tissue of patients with obesity. This could promote virus internalisation into the adipocytes and enhance tumour necrosis factor (TNF) α and IL-6 release. Liver steatosis might also play a role. A Chinese study 57 reported a six-times increased risk of severe COVID-19 in patients with a BMI of more than 25 kg/m² and metabolic associated fatty liver disease compared with patients without obesity. Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis are common in people with abdominal obesity and diabetes. 58 Elevated aspartate aminotransferase concentrations have been associated with poorer prognosis in patients with COVID-19. 23, 59 The extent to which SARS-CoV-2 could directly affect liver function remains to be established as ACE2 is mainly expressed in cholangiocytes. 60 Obesity and diabetes are characterised by chronic lowgrade inflammation with increased concentrations of pro-inflammatory leptin and reduced anti-inflammatory adiponectin. Additionally, people with obesity are often physically inactive, more insulin resistant, and with gut dysbiosis, which might increase the inflammatory response to infection with SARS-CoV-2. Moreover, individuals with obesity have lower vitamin D concentrations, 61 which could also reduce the immune response. The role of vitamin D supplementation is currently being investigated in ongoing clinical trials. SARS-CoV-2 infects not only cells of the upper respiratory system and alveolar epithelial cells in the lung but also, among others, circulating immune cells (CD3, CD4, and CD8 T cells) inducing apoptosis of lymphocytes to an extent that reflects the severity of SARS-CoV-2 infection. 62 As T cells of the adaptive immune system inhibit overactivation of innate immunity, 63 the resulting lymphocytopenia might suppress the innate immune system and enhance secretion of cytokines. 64 The overproduction of pro-inflammatory cytokines (TNFα, IL-6, IL-1β, and CXC-chemokine ligand 10) results in a so-called cytokine storm, which leads to high risk of vascular hyperpermeability, multiorgan failure, and death. 65 High blood concentrations of inflammatory markers (ie, C-reactive protein, procalcitonin, and ferritin), a high neutrophil-to-lymphocyte ratio, and increased blood concentrations of inflammatory cytokines and chemokines have been associated with both COVID-19 severity and death. 13,15,66 Post-mortem analyses of patients with COVID-19 67-69 have revealed inflammatory infiltration of the lungs, heart, spleen, lymph nodes, and kidneys. In those with severe COVID-19, a study 70 found higher concentrations of leukocytes (5·3 vs 4·5 × 10⁹ L, p=0·014), C-reactive protein (47·6 vs 28·7 mg/L, p<0·001), and procalcitonin (0·1 vs 0·05 ng/mL, p<0·001), and lower lymphocyte percentages (median 0·7% [IQR 0·5-1·0] vs 0·8% [0·6-1·2], p=0·048) compared with patients with non-severe COVID-19. Moreover, C-reactive protein concentrations of more than 200 mg/L Review and ferritin concentrations of more than 2500 ng/mL at hospital admission are risk factors for critical Several reports confirmed these results 71,72 and a metaanalysis 66 including more than 3000 patients with COVID-19 identified high concen trations of IL-6, IL-10, and serum ferritin as strong indicators for severe disease. A dysregulated inflammatory innate and adaptive impaired immune response might occur in patients with diabetes, accounting for the systemic tissue damage and respiratory and multiorgan failure. The cytokine storm is more likely to develop in patients with diabetes, as diabetes is already characterised by low-grade chronic inflammation. Moreover, in the case of high viral load, the capacity to raise an acute immune response might be compromised in patients with diabetes, exposing them to more severe adverse effects. One study 21 reported that patients with COVID-19 with diabetes had higher concentrations of inflammation-related bio markers, such as C-reactive protein, serum ferritin, and IL-6, and a higher erythrocyte sedimentation rate, compared with patients with COVID-19 without diabetes. These results were supported by findings from a multicentre study 16 in a Chinese population of patients with COVID-19 (952 with diabetes and 6385 without diabetes), showing that those with diabetes had a higher incidence of lymphopenia (44·5% vs 32·6%), and elevated inflam matory biomarkers (C-reactive protein 57·0% vs 42·4% and procalcitonin 33·3% vs 20·3%]. For patients with COVID-19, those with diabetes are more susceptible to the destructive effect of the cytokine storm than those without diabetes. COVID-19 has been found to be associated with increased coagulation activity. 73 The endothelial dysfunction associated with hypoxia can favour intra-vessel coagulation during COVID-19 infection. Post-mortem studies have found changes in lung vessels, massive pulmonary interstitial fibrosis, variable degrees of haemorrhagic pulmonary infarction, severe endo thelial injury, widespread vascular thrombosis with nearly total occlusion of alveolar capillaries, struc turally deformed capillaries, and growth of new vessels through a mechanism of intussusceptive angio genesis. 46, 74 Moreover, intravascular disseminated coagul ation can be the terminal event in severe COVID-19, 75 and anticoagulant therapy seems to improve prognosis. 53 Diabetes is associated with a prothrombotic state, with an imbalance between clotting factors and fibrinolysis and an increased risk of thromboembolic events. 76 In a retrospective Chinese study 17 in patients with diabetes admitted to hospital for COVID-19, non-survivors had longer prothrombin times and higher concentrations of D-dimer. Patients with COVID-19 with diabetes often present other risk factors such as obesity, older age, and being admitted to hospital that could increase the pro-coagulative state and the risk of thrombotic complications. Despite its syndromic nature, diabetes is still identified as a disturbance of glucose homoeostasis and progressive worsening of hyperglycaemia. In previous infectious disease epidemics, a high glucose concentration was shown to be an independent predictor of death and morbidity. This is likely to also be the case for COVID-19. 11, 77 The role of hyperglycaemia, however, requires a systematic analysis, as suggested by Scheen and colleagues, 78 as the role of glycaemic control before hospital admission, at the time of hospital admission, and during treatment in hospital needs to be considered. A cohort analysis 5 of more than 5500 patients with COVID-19 in the UK found that poor glycaemic control before hospital admission, as indicated by HbA 1c concentrations, was associated with a high risk of in-hospital death. In a model adjusted for sociodemographic variables and comorbidities, the HR for in-hospital death was greater in patients with HbA 1c of 58 mmol/mol (7·5%) or more (3·36, 95% CI 2·18-2·56) than in those with lower HbA 1c (1·50, 1·40-1·60) or those without recent HbA 1c measurement (1·87, 1·63-2·16). 7 Findings from a separate study 24 also suggested a higher risk of mortality from COVID-19 in patients with either type 1 or type 2 diabetes with HbA 1c of more than 86 mmol/mol (10%) compared with those with HbA 1c of less than 48 mmol/mol (6·5%). Surprisingly, in the CORONADO study 23 no association was noted between HbA 1c concentrations and the primary composite outcome (death and tracheal intubation for mechanical ventilation within the first 7 days after hospital admission) in patients with diabetes admitted to hospital with COVID-19. However, the mean HbA 1c value (65 mmol/mol [8·1%]) at admission in this study was higher than the average HbA 1c values (54 mmol/mol [7·1%]) in the age-matched French population in a separate study. 79 Despite no association being found between HbA 1c and outcomes in the CORONADO study, an association was noted between plasma glucose concentration at admission and the primary outcome. In a retrospective study 80 of 85 patients with COVID-19, hyperglycaemia at hospital admission was the best predictor of worst chest radiographic imaging results. Another study 81 found a higher risk of a composite outcome (ICU admission, mechanical ventilation, and death) in patients with hyperglycaemia at admission (fasting blood glucose >7 mmol/L) and without history of diabetes compared with patients without diabetes and normoglycaemia (OR 5·47, 95% CI 1·56-19·82). This finding is supported by results from a retrospective analysis 82 that showed death occurred in 40 of 96 uncontrolled patients with hyperglycaemia (41·7%) compared with deaths in 13 of 88 patients with diabetes (14·8%, p<0·001) . Altogether, Review these results highlight the need for improving glycaemic control in all patients presenting with hyperglycaemia, irrespective of a known diagnosis of diabetes. Random hyperglycaemia during treatment in hospital was noted to contribute to worse prognosis for patients with COVID-19 in Wuhan. 83 In 1122 patients with COVID-19 admitted to hospital in the USA, 84 the mortality rate was four times higher in those with diabetes or hyperglycaemia during the hospital stay (28·8%) than those with normoglycaemia (6·2%). Moreover, mortality was higher in those with hyper glycaemia and without known diabetes than in patients with known diabetes. 84 Another study 77 showed that hyperglycaemia during treatment in hospital was a risk factor for death in patients with severe COVID-19 (adjusted HR 1·8, 95% CI 1·1-2·8). Patients with COVID-19 with diabetes 16 with an inhospital median blood glucose concentration of less than 6·4 mmol/L (IQR 5·2-7·5) had lower incidences of lymp hopenia (30·5% vs 49·6%), neutrophilia (10·7% vs 19·4%), increases in C-reactive protein (47·5% vs 59⋅5%), and procalcitonin (24·2% vs 35·0%) than patients with a median blood glucose concentration of 7·5 mmol/L or higher. Good glycaemic control was also associated with a lower rate of complications and allcause mortality. 16 These results were confirmed in a propensity-matched score analysis, matching diabetesrelated comorbidities. 16 An unusually high number of COVID-19 patients developing diabetic ketoacidosis or hyper glycaemic hyperosmolar syndrome have been noted 85 and negative outcomes during COVID-19 have been reported in two clinical cases of diabetic ketoacidosis and hyperglycaemic hyperosmolar syndrome. 86 In one analysis, 87 ketosis occurred in 6·4% of patients with COVID-19 and its prevalence rose to 11·6% in patients with COVID-19 with diabetes, resulting in a high mortality rate (33·3%). In the CORONADO study, 23 11·1% of the participants had diabetes-related disorders at admission including 132 patients with severe hyperglycaemia and 40 with ketosis, of whom 19 had diabetic ketoacidosis. Although ketosis might have resulted from discontinuation of glucose-lowering drugs because of anorexia before hospital admission, a direct effect of SARS-CoV-2 should be considered. The virus binds to ACE2 receptors, which, among other locations, are expressed in pancreatic tissue and β-cells in particular. 36 Therefore, an acute loss of insulin secretory capacity along with a stress condition and the cytokine storm could lead to a rapid metabolic deterioration with development of diabetic ketoacidosis or hyper glycaemic hyperosmolar syndrome. Additionally, hyper glycaemic hyperosmolar syndrome is likely to increase the risk of thrombosis that already characterises severe COVID-19. Because of the severity of diabetic keto acidosis in patients with COVID-19, ad hoc recommen dations for its treatment have been released in the UK. 85 The SARS-Cov-2 tropism for the β-cell could cause acute impairment of insulin secretion or destruction of β-cells resulting in de novo development of diabetes. This hypothesis is supported by a previous observation 88 that infection with human herpesvirus 8 in a sub-Saharan African population induced ketosis-prone type 2 diabetes. In line with this view, new-onset diabetes has been reported in patients with COVID-19 being treated in hospital. 82, 89 In a population of 453 patients with COVID-19, 82 94 were identified with new-onset diabetes (defined as first recognition of fasting plasma glucose ≥7 mmol/L and HbA 1c ≥48 mmol/mol (6·5%) at hospital admission); additionally, these individuals had a greater risk of mortality (HR 9·42, 95% CI 2·18 0-40·7) than those with hyperglycaemia (3·29, 0·65-16·6) or diabetes (4·63, 1·02-21·0). In summary, poor glycaemic control at hospital admission and during the hospital stay worsens outcomes for patients with COVID-19. Moreover, consider ation should be given for a direct effect of SARS-CoV-2 on β-cell function and survival, causing worsening rapid and severe deterioration of metabolic control in people with pre-existing diabetes or leading to the development of new-onset diabetes (figure). In people with hyperglycaemia, glycaemic control should be ensured to reduce the risk of threatening metabolic com plications The relationship between diabetes and COVID-19 is biunivocal. On one hand, people with diabetes have worse outcomes because of multiple associated conditions enhancing the risk. On the other hand, SARS-CoV-2, because of its tropism for the β-cell, might cause new-onset diabetes or sustain hyperglycaemia at hospital admission. The impairment of β-cell function along with the inflammatory cytokine storm and counter-regulatory hormonal responses can precipitate further acute metabolic complications (DKA or HHS). New-onset diabetes, hyperglycaemia at admission, and acute metabolic deterioration, in turn, can further worsen COVID-19 outcomes. DKA=diabetic ketoacidosis. HHS=hyperglycaemic hyperosmolar syndrome. (table 2) , which should integrate all therapeutic manoeuvres put in place to reduce the risk of severe outcomes and mortality. Finally, achievement and maintenance of glycaemic control should take into consideration the implications of the use of different glucose-lowering agents in the setting of COVID-19. Use of glucose-lowering agents might raise specific considerations in patients with COVID-19 (table 3) . In the presence of mild COVID-19 in an out-patient setting, usual glucose-lowering therapies for patients with diabetes could be continued if the patient eats and drinks adequately and a more frequent blood glucose-monitoring regimen is implemented. 90 Patients admitted to hospital for severe COVID-19 might need modifications to their diabetes therapy, including withdrawing ongoing treatments and initiating insulin therapy. Such a decision should be based on the severity of COVID-19, nutritional status, actual glycaemic control, risk of hypoglycaemia, renal function, and drug interactions. Although insulin treatment has been recommended in patients with diabetes with severe COVID-19, 90 one study 28 showed worse clinical outcomes and a worse laboratory results profile in patients on insulin compared with those on metformin. Nonetheless, these results should be viewed with caution because of potential confounding by indication, as insulin treatment could have been used simply because the diabetes was more severe. In keeping with this hypothesis, another study found that insulin infusion allowed achievement of glycaemic targets and improved outcomes in patients with hyperglycaemia with COVID-19. 18 Despite better outcomes reported in patients with COVID-19 with diabetes treated with metformin, 28 the drug should be stopped in patients with respiratory distress, renal impairment, or heart failure 90 because of a risk of lactic acidosis. A favourable effect of metformin in patients with COVID-19 has been hypothesised as the drug might prevent virus entry into target cells via adenosine monophosphate-activated protein kinase activation and the phosphatidylinositol-3-kinase-protein kinase B-mammalian target of rapamycin signalling pathway. 91 A hypothetical anti-viral effect of SGLT2-inhibitors has also been suggested as these agents can decrease intracellular pH and increase lactate concentrations that could reduce the viral load. 92 Nonetheless, SGLT2 inhibitors require optimal hydration to avoid hypovolemia and electrolyte imbalance, and proper adjustment of insulin doses because of the risk of diabetic ketoacidosis. GLP-1 receptor agonists might aggravate anorexia and should be discontinued in severely ill patients with COVID-19 because of a potential risk of aspiration pneumonia. 90 Nonetheless, their associated anti-inflammatory actions 93 and lung protection should be evaluated since preclinical studies have suggested that GLP-1 receptor agonists might attenuate pulmonary inflammation and preserve lung function in rats with experimental lung injury 94 and respiratory syncytial virus infection. 95 DPP-4 inhibitors are associated with a low risk of hypoglycaemia and can be used for a wide renal function range. DPP-4 inhibitors are generally well tolerated and, in experimental studies, they were shown to mitigate inflammatory response. 96 Because soluble DPP-4 might act as a co-receptor for a subset of coronaviruses, 97 DPP-4 inhibitors might interfere with and modify such binding and hypothetically reduce virulence. 98 However, there is no clinical evidence of such an advantage and in 23, 28 no association was found between individual glucose-lowering drugs and outcomes. Because of the risk of hypoglycaemia, sulfonylureas should be stopped in patients with diabetes with COVID-19, particularly if oral intake is poor or chloroquine is simultaneously used. 99 Pioglitazone has anti-inflammatory properties, and in experimental animal models it reduced lung inflammation and fibrosis. 100, 101 Nonetheless, the use of pioglitazone in patients with diabetes with COVID-19 is controversial because of the risk of fluid retention and oedema in haemodynamically unstable patients. Medical teams should ensure adequate glycaemic control in patients with diabetes with COVID-19. This requires considering all potential implications that therapies for COVID-19 might generate when used in patients with diabetes. Treatment with chloroquine or hydroxychloroquine can cause hypoglycaemia, particularly in patients on insulin or sulfonylureas, because of their effects on insulin secretion, degradation, and action. 99 Conversely, antiviral drugs such as lopinavir and ritonavir could lead to hyperglycaemia and worsen glycaemic control. 102 These agents can cause hepatic and muscle toxicity so caution is recommended when they are used in combination with statins and in patients with fatty liver disease. 103 Pharmacokinetic interactions with antidiabetic drugs are also common, causing over-exposure or under-exposure to either anti virals or anti-diabetic drugs. 104 Glucocorticoids have been used in patients with COVID-19 with severe acute respiratory distress syndrome as symptomatic and anti-inflammatory treat ment. Their use, however, can worsen insulin resistance, sustain gluconeogenesis, worsen glycaemic control, and cause marked hyperglycaemia. As known, glucocorticoids exert their hyperglycaemic effects by reducing insulin sensitivity and insulin secretion, and also by interfering with GLP-1 effects, and enhancing production of glucagon. People with diabetes with COVID-19 are at a greater risk of worse prognosis and mortality. Given the high worldwide prevalence of diabetes, these individuals represent a large vulnerable segment of the COVID-19 population. The poorer prognosis of people with diabetes is the likely consequence of the syndromic nature of the disease (figure): hyperglycaemia, older age, comorbidities, and in particular hypertension, obesity, and cardio vascular disease all contribute to increase the risk in these individuals. The picture, however, is more complicated as it requires factoring in societal factors such as deprivation and ethnicity as well as factors that become relevant at the time that a patient with severe COVID-19 needs to be managed. Here, a physician has to account for not only the health status of the person with diabetes but also to balance carefully glucose-lowering treatments with specific treatments for the viral infection. Once again, diabetes management in patients with COVID-19 poses a great clinical challenge, one that requires a much-integrated team approach, as this is an indispensable strategy to reduce the risk of medical complications and death as much as possible. Careful assessment of the many components that contribute to poor prognosis with COVID-19 in patients with diabetes might represent the best, if not the only way to overcome Usual at home antidiabetic therapy can be maintained in patients receiving treatment in hospital with regular caloric and fluid intake according to the clinical status, risk of drug-related adverse effects, and interactions between antidiabetic agents and drugs used for the treatment of COVID-19. However, insulin is the preferred agent for glycaemic control in patients with diabetes receiving treatment in hospital, and its use is mandatory in critically ill patients. N/A=not applicable. We searched PubMed for articles using the search terms "diabetes mellitus", "Type 1 diabetes mellitus", "Type 2 diabetes mellitus", "new onset diabetes", "outcome", "age", "gender", "ethnicity", "comorbidities", "hypertension", "cardiovascular disease", "obesity", "inflammation", "coagulation", "hyperglycaemia", "ketoacidosis" , "antidiabetic drug", "ACE-inhibitors", and "hydroxychloroquine", in conjunction with the terms "COVID-19" and "SARS-CoV-2 infection". No criteria for publication data were set, and all articles in English were included if published before June 30, 2020. We also checked reference lists in relevant articles and Google Scholar for additional references. the current situation and enable our health systems to be ready to face any future challenges in a prompt and effective manner. Finally, the inter-relationship between diabetes and COVID-19 should trigger more research to understand the extent to which specific mechanisms of the virus (eg, its tropism for the pancreatic β-cell) might contribute to worsening of glycaemic control and, in some cases, to the striking development of diabetic ketoacidosis or hyper glycaemic hyperosmolar syndrome, and possibly the development of new-onset diabetes. MA, MCC, MM, and LM contributed equally to this manuscript preparation by doing the literature search, critically selecting data from the literature, writing the manuscript draft, and preparing tables and drawing figures. AC and SDP designed the review structure and literature search, and finalised the manuscript. SDP reports grants and personal fees from AstraZeneca, Boheringer Ingelheim, and Novartis Pharmaceuticals; and personal fees from Eli Lilly, GlaxoSmihKline, Janssen, Novo Nordisk A/S, Laboratoires Servier, Sanofi, and Takeda Pharmaceuticals. All other authors declare no competing interests. COVID-19 disease in Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes Clinical characteristics and outcomes of patients with severe covid-19 with diabetes Outcomes in patients with hyperglycemia affected by Covid-19: can we do more on glycemic control? Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis Type 1 and type 2 diabetes and COVID-19 related mortality in England: a whole population study Diabetes is a risk factor for the progression and prognosis of COVID-19 Portale di epidemiologia per gli operatori sanitari Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study Type 1 and type 2 diabetes and COVID-19 related mortality in England: a cohort study in people with diabetes Type 1 diabetes and COVID-19: preliminary findings from a multicenter surveillance study in the US Disparities in age-specific morbidity and mortality from SARS-CoV-2 in China and the Republic of Korea The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication At the heart of the matter: unmasking and addressing COVID-19's toll on diverse populations Impact of climate and public health interventions on the COVID-19 pandemic: a prospective cohort study Kidney disease is associated with in-hospital death of patients with COVID-19 Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats Renin-angiotensin system research: from molecules to the whole body Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and metaanalysis Reninangiotensin-aldosterone system blockers and the risk of Covid-19 Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension Renin-angiotensinaldosterone system inhibitors and risk of Covid-19 COVID-19-related myocarditis in a 21-year-old female patient Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities The impact of 2019 novel coronavirus on heart injury: a systemic review and meta-analysis Myocardial injury and COVID-19: possible mechanisms Prevalence of obesity among adult inpatients with COVID-19 in France Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation COVID-19 and its implications for thrombosis and anticoagulation Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study Obesity accompanying COVID-19: the role of epicardial fat Clinical importance of epicardial adipose tissue Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease Global epidemiology of non-alcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes Longitudinal association between markers of liver injury and mortality in COVID-19 in China Hypertransaminasemia in the course of infection with SARS-CoV-2: incidence and pathogenetic hypothesis Vitamin-D and COVID-19: do deficient risk a poorer outcome? Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Not so fast: adaptive suppression of innate immunity COVID-19 pandemic, coronaviruses, and diabetes mellitus Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis Pathological findings of COVID-19 associated with acute respiratory distress syndrome The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. medRxiv 2020 Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Clinical and immunologic features in severe and moderate coronavirus disease 2019 Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia Type 2 diabetes: an atherothrombotic syndrome Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Prognostic factors in patients with diabetes hospitalized for COVID-19: findings from the CORONADO study and other recent reports Trends in the quality of care for elderly people with type 2 diabetes: the need for improvements in safety and quality (the 2001 and 2007 ENTRED surveys) Admission hyperglycemia and radiological findings of SARS-COV-2 in patients with and without diabetes The clinical characteristics and outcomes of patients with diabetes mellitus and secondary hyperglycaemia with coronavirus disease 2019: a single-center, retrospective, observational study in Wuhan Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States Clinical characteristics of 28 patients with diabetes and COVID-19 in Wuhan Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States Guidance on the management of diabetic ketoacidosis in the exceptional circumstances of the COVID-19 pandemic Acute hyperglycemic crises with coronavirus disease-19: case reports COVID-19 infection may cause ketosis and ketoacidosis Ketosis-prone type 2 diabetes mellitus and human herpesvirus 8 infection in sub-Saharan Africans Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus Practical recommendations for the management of diabetes in patients with COVID-19 Metformin in COVID-19: a possible role beyond diabetes Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice Glucagon-like peptide 1 receptor signaling attenuates respiratory syncytial virusinduced type 2 responses and immunopathology DPP4 regulates the inflammatory response in a rat model of febrile seizures Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC COVID-19 and diabetes: can DPP4 inhibition play a role? Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis The role of pro-and antiinflammatory responses in silica-induced lung fibrosis Recommended first-line antiretroviral therapy regimens and risk of diabetes mellitus in HIV-infected adults in resource-limited settings Hepatotoxicity and antiretroviral therapy with protease inhibitors: a review Liverpool COVID-19 interactions This paper was supported by the research grant Punteggio Rating from the University of Pisa (Pisa, Italy).